RecruitingNCT03356236

Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation

A Multicenter, Prospective Cohort Study Investigating Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation

Sponsor

Yue Han

Enrollment

828 participants

Start Date

Apr 17, 2018

Study Type

OBSERVATIONAL

Conditions

Hepatocarcinoma

Summary

To evaluate the efficacy and safety of Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma following Local Ablation

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing whether a traditional Chinese herbal medicine called Huaier Granules, taken after a local ablation treatment (a procedure that destroys tumors using heat or cold) for liver cancer (hepatocellular carcinoma), can reduce the chance of the cancer coming back or spreading. **You may be eligible if...** - You are between 18 and 75 years old (male or female) - You have been diagnosed with liver cancer through tissue examination or standard imaging criteria - Imaging shows your cancer cells have been eliminated after ablation treatment - Your blood counts, liver, and kidney function meet the required levels **You may NOT be eligible if...** - Your cancer has spread to other parts of the body - You have other serious liver conditions - You have had previous treatments that make you ineligible - Your overall health is too poor to participate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(17)

The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

Shijiazhuang Fifth Hospital

Shijiazhuang, Hebei, China

Affiliated Cancer Hospital of Harbin Medical University

Harbin, Heilongjiang, China

Henan Cancer Hospital

Zhengzhou, Henan, China

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

Wuhan, Hubei, China

The Affiliated Zhongshan Hospital of Dalian University

Dalian, Liaoning, China

The Second Hospital of Dalian Medical University

Dalian, Liaoning, China

Shandong Provincial Hospital

Jinan, Shandong, China

The Second Hospital of Shandong University

Jinan, Shandong, China

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China

First Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, China

the Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Beijing You 'an Hospital, Capital Medical University

Beijing, China

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Beijing, China

Chinese PLA General Hospital

Beijing, China

Chongqing Cancer Hospital

Chongqing, China

Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03356236

Related Trials

Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches

NCT074323471 location

Prediction of Decompensation and HCC Development in Advanced Chronic Liver Disease

NCT065236081 location

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

NCT037557391 location

METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors

NCT057940481 location

A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)

NCT060287241 location